Nexscient, Inc.

Nexscient, Inc. Annual Report - Plain-English Breakdown for Investors
Your quick guide to their 2023 performance

---

1. This Year’s Performance

Nexscient uses AI to speed up drug discovery for pharmaceutical companies. In 2023:

• Growth: Added 3 major pharma clients, 2 drugs they helped develop entered final testing.
• Stock price: Rose 22% this year.
• But… Still no profits, and total losses since founding hit $890 million.

---

2. Financial Health

• Revenue: $220 million (+18% from 2022).
• Losses: -$45 million (improved from -$62M in 2022).
• Spending: Pumped $180M into R&D to upgrade AI tools.
• Cash runway: $300M left (~14 months at current spending).

Verdict: Growing revenue but burning cash. Raised $70M this year to stay afloat.

---

3. Wins & Challenges

What worked ✅

• Their AI spotted a drug side effect humans missed.
• Partnerships with 3 top-10 pharma companies.
• Reduced losses by 27% year-over-year.

What didn’t ❌

• A key drug trial failed, costing $15M.
• Total debt increased to $70M (up from $30M last year).

---

4. Key Risks

• Science risk: If 2024 drug trials fail, stock could plummet.
• Funding needs: Likely to raise $150M+ in 2024, which could dilute shares.
• AI regulation: New rules could delay projects.

---

5. Leadership Moves

• New CEO Maya Patel (ex-Google Health) launched a $200K pilot to sell AI tools directly to hospitals.
• Hired 45 new AI researchers (total team: 300).

---

6. What’s Next in 2024

• Make-or-break: Results from 2 late-stage drug trials due Q3.
• Expect another fundraising round (loans or stock sales).

---

7. Competition Check

• Advantage: Faster AI than smaller rivals.
• Disadvantage: Budget is 10x smaller than giants like BioAI Labs.

---

Key Investor Takeaways

1. Progress, not profits: Revenue grew, losses shrank, but still no earnings.
2. High stakes ahead: 2024 trial results will decide if their AI delivers real-world value.
3. Risky but intriguing: A bet on AI disrupting drug development. Only invest if you’re comfortable with volatility.

This is a high-risk, high-reward stock. Not for cautious investors.

---

Report based on Nexscient’s 2023 disclosures. Always do your own research before investing. 😊